Clinical Trials on Resectable Head and Neck Squamous Cell Carcinoma

Total 17756 results

Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
Medical College of Wisconsin

Recruiting

Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)

Resectable Head and Neck Squamous Cell Carcinoma

United States
Chase Heaton, MD
Incyte Corporation; OncoSec Medical Incorporated

Terminated

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma

United States
Arnaud Bewley, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States
National Cancer Institute (NCI)

Active, not recruiting

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Withdrawn

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma
University Health Network, Toronto
AstraZeneca; Mirati Therapeutics Inc.

Withdrawn

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001)

Squamous Cell Carcinoma, Head And Neck | Squamous Cell Carcinoma Mouth | Resectable Squamous Cell Carcinoma of Oral Cavity

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell Carcinoma

United States
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Hi-Q Marine Biotech International, Ltd.

Recruiting

A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

Squamous Cell Carcinomas of the Head and Neck

Taiwan
Xuekui Liu

Not yet recruiting

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma (CZCNRHNSCC)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI); Canceropôle Ile de France

Completed

Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients (EGéSOR)

Head and Neck Squamous Cell Carcinomas (HNSCCs)

France
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Washington University School of Medicine
Merck Sharp & Dohme LLC

Active, not recruiting

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and Neck

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...

United States
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States
Washington University School of Medicine

Active, not recruiting

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and Neck

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
Yonsei University

Completed

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Head Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell Metastatic

Korea, Republic of
Eben Rosenthal
National Cancer Institute (NCI)

Completed

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
University of Pittsburgh
National Cancer Institute (NCI)

Terminated

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and Neck

United States
National Taiwan University Hospital

Unknown

Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.

Head-and-Neck Squamous Cell Carcinoma

Taiwan
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Patients With Head and Neck Cancer. (ProNiHN)

Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

France
Andrei Iagaru

Not yet recruiting

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head-and-neck Squamous Cell Carcinoma

United States
Technische Universität Dresden
German Cancer Research Center; National Center for Tumor Diseases, Heidelberg; Radiation Oncology Working Group of the German Cancer Society and other collaborators

Recruiting

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas (DELPHI)

Head-and-neck Squamous Cell Carcinoma

Germany
Case Comprehensive Cancer Center

Not yet recruiting

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
Rakuten Medical, Inc.

Active, not recruiting

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma

United States
National Cancer Institute, Egypt

Recruiting

Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell Carcinoma

Head and Neck Carcinoma

Egypt
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

Spain, United States, Italy, Korea, Republic of, United Kingdom, Vietnam, France, Japan, Brazil, India, Thailand, Germany, Canada, Turkey, Malaysia, Taiwan, Belgium, Austria, Hungary
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; IO Biotech

Recruiting

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (KIEO)

Head and Neck Squamous Cell Carcinoma

United States
Tianjin Medical University General Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Memorial Sloan Kettering Cancer Center

Completed

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Robert Ferris
Bristol-Myers Squibb

Completed

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
Robert Ferris
Immune Cell Therapy Inc.

Withdrawn

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma

United States
Shyam S.D. Rao
National Cancer Institute (NCI)

Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Metastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals

Recruiting

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer | Neck Cancer | Head Cancer Neck

United States
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (APA)

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and Neck

United States
Royal Marsden NHS Foundation Trust

Recruiting

Liquid Biopsy for Early DiagNosis of Squamous Cell Carcinoma of the HeAd and NeCk rEgion (ENHANCE)

Head and Neck Squamous Cell Carcinoma

United Kingdom
Biotech Pharmaceutical Co., Ltd.

Completed

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN (Redbull-1)

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
RTOG Foundation, Inc.
Bristol-Myers Squibb

Completed

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States

Clinical Trials on Resectable Head and Neck Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations